CVA Family Office LLC raised its position in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 9.3% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 8,399 shares of the company’s stock after purchasing an additional 715 shares during the quarter. CVA Family Office LLC’s holdings in Johnson & Johnson were worth $1,302,000 as of its most recent SEC filing.
A number of other large investors have also made changes to their positions in JNJ. Moneta Group Investment Advisors LLC grew its stake in shares of Johnson & Johnson by 90,144.4% during the 4th quarter. Moneta Group Investment Advisors LLC now owns 54,386,720 shares of the company’s stock valued at $9,607,414,000 after purchasing an additional 54,326,454 shares during the period. Norges Bank bought a new position in shares of Johnson & Johnson during the 4th quarter valued at approximately $4,609,399,000. Morgan Stanley grew its stake in shares of Johnson & Johnson by 12.0% during the 4th quarter. Morgan Stanley now owns 42,224,521 shares of the company’s stock valued at $7,458,962,000 after acquiring an additional 4,521,062 shares during the period. Nordwand Advisors LLC bought a new position in shares of Johnson & Johnson during the 4th quarter valued at approximately $785,273,000. Finally, Price T Rowe Associates Inc. MD grew its stake in shares of Johnson & Johnson by 15.1% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 29,277,774 shares of the company’s stock valued at $5,171,919,000 after acquiring an additional 3,849,148 shares during the period. 67.57% of the stock is currently owned by institutional investors.
Wall Street Analyst Weigh In
A number of brokerages recently issued reports on JNJ. Morgan Stanley reiterated an “equal weight” rating and set a $187.00 price objective on shares of Johnson & Johnson in a research note on Friday. StockNews.com began coverage on Johnson & Johnson in a research note on Thursday, May 18th. They set a “strong-buy” rating for the company. Citigroup initiated coverage on Johnson & Johnson in a research note on Tuesday, May 30th. They set a “buy” rating and a $185.00 price objective for the company. Stifel Nicolaus upped their price target on Johnson & Johnson from $165.00 to $175.00 in a research note on Friday. Finally, UBS Group initiated coverage on Johnson & Johnson in a research note on Tuesday, March 28th. They issued a “neutral” rating and a $164.00 price target for the company. Eight analysts have rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Johnson & Johnson has an average rating of “Hold” and an average price target of $171.40.
Johnson & Johnson Stock Performance
Johnson & Johnson (NYSE:JNJ – Get Free Report) last released its quarterly earnings results on Thursday, July 20th. The company reported $2.80 earnings per share for the quarter, beating the consensus estimate of $2.62 by $0.18. Johnson & Johnson had a return on equity of 36.13% and a net margin of 13.22%. The company had revenue of $25.53 billion for the quarter, compared to analyst estimates of $24.63 billion. During the same quarter in the prior year, the firm posted $2.59 EPS. Johnson & Johnson’s quarterly revenue was up 6.3% compared to the same quarter last year. On average, sell-side analysts anticipate that Johnson & Johnson will post 10.65 earnings per share for the current year.
Johnson & Johnson Announces Dividend
The business also recently declared a quarterly dividend, which will be paid on Thursday, September 7th. Investors of record on Monday, August 28th will be issued a dividend of $1.19 per share. The ex-dividend date of this dividend is Friday, August 25th. This represents a $4.76 annualized dividend and a yield of 2.80%. Johnson & Johnson’s payout ratio is presently 99.58%.
Insider Activity at Johnson & Johnson
In other Johnson & Johnson news, EVP Kathryn E. Wengel sold 12,465 shares of the company’s stock in a transaction on Monday, June 12th. The stock was sold at an average price of $160.00, for a total value of $1,994,400.00. Following the transaction, the executive vice president now owns 65,934 shares of the company’s stock, valued at approximately $10,549,440. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.20% of the stock is currently owned by insiders.
Johnson & Johnson Profile
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.
Featured Articles
- Five stocks we like better than Johnson & Johnson
- MarketBeat Week in Review – 7/17 – 7/21
- U.S. Bancorp Shares Rally As Analysts Get Bullish After Q2 Report
- AutoNation Beats Earnings Expectations, Stock Down?
- American Express Hiccups After Earnings, Time To Buy?
- ISRG Stock Sinks After Strong Earnings: Is the Growth Priced In?
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
